Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ch5126766
2. Ro5126766
1. 946128-88-7
2. Ro5126766
3. Ro-5126766
4. Ch5126766
5. Ro-5126766 Free Base
6. Avutometinib
7. Ro 5126766
8. Ch-5126766
9. Rg-7304
10. Cki-27
11. Ro5126766(ch5126766)
12. Chebi:78825
13. Ro 5126766 - Bio-x
14. Vs-6766
15. Chembl3264002
16. Ro5126766 (ch5126766)
17. D0d4252v97
18. R-7304
19. N-(3-fluoro-4-{[4-methyl-2-oxo-7-(pyrimidin-2-yloxy)-2h-chromen-3-yl]methyl}pyridin-2-yl)-n'-methylsulfuric Diamide
20. Sulfamide, N-(3-fluoro-4-((4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2h-1-benzopyran-3-yl)methyl)-2-pyridinyl)-n'-methyl-
21. 3wig
22. Chu
23. Avutometinib [inn]
24. Schembl960093
25. Unii-d0d4252v97
26. Gtpl11867
27. Bcp21067
28. Ex-a2151
29. Bdbm50010462
30. Nsc758248
31. Nsc800871
32. S7170
33. Zinc68247388
34. Akos030527032
35. Ccg-269457
36. Compound 1 [pmid: 24900832]
37. Cs-5254
38. Db15254
39. Nsc-758248
40. Nsc-800871
41. Sb16628
42. Ro 5126766 [who-dd]
43. Ac-35949
44. Da-40233
45. Hy-18652
46. Ch 5126766
47. Ft-0737411
48. A916428
49. Ro5126766; Ch5126766
50. Q27147976
51. Ro 5126766; Ro5126766; Ch5126766; Ch5126766; Ch 5126766
52. 3-[(2-((n-methylsulfamoyl)amino)-3-fluoropyridin-4-yl)methyl]-4-methyl-7-(pyrimidin-2-yloxy)-chromen-2-one
53. 3-[[3-fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]-4-methyl-7-pyrimidin-2-yloxychromen-2-one
54. N-(3-fluoro-4-((4-methyl-2-oxo-7-(pyrimidin-2-yloxy)-2h-chromen-3-yl)methyl)pyridin-2-yl)-n'-methylsulfamide
| Molecular Weight | 471.5 g/mol |
|---|---|
| Molecular Formula | C21H18FN5O5S |
| XLogP3 | 2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 7 |
| Exact Mass | 471.10126803 g/mol |
| Monoisotopic Mass | 471.10126803 g/mol |
| Topological Polar Surface Area | 141 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 845 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Avutometinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Avutometinib, including repackagers and relabelers. The FDA regulates Avutometinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Avutometinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Avutometinib supplier is an individual or a company that provides Avutometinib active pharmaceutical ingredient (API) or Avutometinib finished formulations upon request. The Avutometinib suppliers may include Avutometinib API manufacturers, exporters, distributors and traders.
Avutometinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Avutometinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Avutometinib GMP manufacturer or Avutometinib GMP API supplier for your needs.
A Avutometinib CoA (Certificate of Analysis) is a formal document that attests to Avutometinib's compliance with Avutometinib specifications and serves as a tool for batch-level quality control.
Avutometinib CoA mostly includes findings from lab analyses of a specific batch. For each Avutometinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Avutometinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Avutometinib EP), Avutometinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Avutometinib USP).
LOOKING FOR A SUPPLIER?
